These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22766359)

  • 1. Probing the cation binding modes of macrocyclic HCV protease inhibitor BILN 2061 by multinuclear NMR.
    Busacca CA; Jones PJ; Campbell SJ; Saha AK; Gonnella NC; Senanayake CH
    J Pharm Biomed Anal; 2012 Nov; 70():609-13. PubMed ID: 22766359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
    Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
    Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis.
    Yee NK; Farina V; Houpis IN; Haddad N; Frutos RP; Gallou F; Wang XJ; Wei X; Simpson RD; Feng X; Fuchs V; Xu Y; Tan J; Zhang L; Xu J; Smith-Keenan LL; Vitous J; Ridges MD; Spinelli EM; Johnson M; Donsbach K; Nicola T; Brenner M; Winter E; Kreye P; Samstag W
    J Org Chem; 2006 Sep; 71(19):7133-45. PubMed ID: 16958506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
    Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
    Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061.
    Shu C; Zeng X; Hao MH; Wei X; Yee NK; Busacca CA; Han Z; Farina V; Senanayake CH
    Org Lett; 2008 Mar; 10(6):1303-6. PubMed ID: 18293994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
    Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
    Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
    Geitmann M; Dahl G; Danielson UH
    J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
    Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
    Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
    Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
    J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
    Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
    Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.